BACKGROUND: Neurofilament light (NfL) levels reflect inflammatory disease activity in multiple sclerosis (MS), but it is less clear if NfL also can serve as a biomarker for MS progression in treated patients without relapses and focal lesion accrual. In addition, it has not been well established if clinically effective treatment re-establishes an age and sex pattern for cerebrospinal fluid NfL (cNfL) as seen in controls, and to what degree levels are affected by disability level and magnetic resonance imaging (MRI) atrophy metrics. METHODS: We included subjects for whom cNfL levels had been determined as per clinical routine or in clinical research, classified as healthy controls (HCs, n = 89), MS-free disease controls (DCs, n = 251), untreated MS patients (uMS; n = 296), relapse-free treated MS patients (tMS; n = 78), and ProTEct-MS clinical trial participants (pMS; n = 41). RESULTS: Using linear regression, we found a positive association between cNfL and age, as well as lower concentrations among women, in all groups, except for uMS patients. In contrast, disability level in the entire MS cohort, or T1 and T2 lesion volumes, brain parenchymal fraction, thalamic fraction, and cortical thickness in the pMS trial cohort, did not correlate with cNfL concentrations. Furthermore, the cNfL levels in tMS and pMS groups did not differ. CONCLUSIONS: In participants with MS lacking signs of inflammatory disease activity, disease modulatory therapy reinstates an age and sex cNfL pattern similar to that of control subjects. No significant association was found between cNfL levels and clinical worsening, disability level, or MRI metrics.

Centre for Molecular Medicine Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden

Centre for Neurology Academic Specialist Center Karolinska University Hospital Stockholm Sweden

Department of Clinical Neurosciences Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Neuroradiology Karolinska University Hospital Stockholm Sweden

Neurologic Clinic and Policlinic MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel Basel Switzerland

Zobrazit více v PubMed

Akamine, S. , Marutani, N. , Kanayama, D. , Gotoh, S. , Maruyama, R. , Yanagida, K. , Sakagami, Y. , Mori, K. , Adachi, H. , Kozawa, J. , Maeda, N. , Otsuki, M. , Matsuoka, T. , Iwahashi, H. , Shimomura, I. , Ikeda, M. , & Kudo, T. (2020). Renal function is associated with blood neurofilament light chain level in older adults. Scientific Reports, 10(1), 20350. 10.1038/s41598-020-76990-7 PubMed DOI PMC

Alagaratnam, J. , Von Widekind, S. , De Francesco, D. , Underwood, J. , Edison, P. , Winston, A. , Zetterberg, H. , & Fidler, S. (2021). Correlation between CSF and blood neurofilament light chain protein: A systematic review and meta‐analysis. BMJ Neurology Open, 3(1), e000143. 10.1136/bmjno-2021-000143 PubMed DOI PMC

Alping, P. , Piehl, F. , Langer‐Gould, A. , & Frisell, T. (2019). Validation of the Swedish multiple sclerosis register: Further improving a resource for pharmacoepidemiologic evaluations. Epidemiology (Cambridge, Mass.), 30(2), 230–233. 10.1097/EDE.0000000000000948 PubMed DOI PMC

Axelsson, M. , Malmestrãm, C. , Nilsson, S. , Haghighi, S. , Rosengren, L. , & Lycke, J. (2011). Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. Journal of Neurology, 258(5), 882–888. 10.1007/s00415-010-5863-2 PubMed DOI

Bar‐Or, A. , Thanei, G.‐A. , Harp, C. T. , Cross, A. H. , Hauser, S. L. , Kuhle, J. , Leppert, D. , Oksenberg, J. , Model, F. , Fiore, D. , Koendgen, H. , Mehta, L. , Hendricks, R. , Fischer, S. , Manfrini, M. , & Herman, A. E. (2019). Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment. Multiple Sclerosis Journal, 25(S2), 52–52. 10.1177/1352458519868070 DOI

Barro, C. , Chitnis, T. , & Weiner, H. L. (2020). Blood neurofilament light: A critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology, 7(12), 2508–2523. 10.1002/acn3.51234 PubMed DOI PMC

Benkert, P. , Meier, S. , Schaedelin, S. , Manouchehrinia, A. , Yaldizli, A. Z. , Maceski, A. , Oechtering, J. , Achtnichts, L. , Conen, D. , Derfuss, T. , Lalive, P. H. , Mueller, C. , Maller, S. , Naegelin, Y. , Oksenberg, J. R. , Pot, C. , Salmen, A. , Willemse, E. , Kockum, I. , & Blennow, K. (2022). Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. The Lancet Neurology, 21(3), 246–257. 10.1016/S1474-4422(22)00009-6 PubMed DOI

Bhan, A. , Jacobsen, C. , Dalen, I. , Bergsland, N. , Zivadinov, R. , Alves, G. , Myhr, K.‐M. , & Farbu, E. (2021). CSF neurofilament light chain predicts 10‐year clinical and radiologic worsening in multiple sclerosis. Multiple Sclerosis Journal—Experimental, Translational and Clinical., 7(4), 205521732110603. 10.1177/20552173211060337 PubMed DOI PMC

Bittner, S. , Oh, J. , Havrdovã, E. K. , Tintorã, M. , & Zipp, F. (2021). The potential of serum neurofilament as biomarker for multiple sclerosis. Brain, 144(10), 2954–2963. 10.1093/brain/awab241 PubMed DOI PMC

Bridel, C. , Van Wieringen, W. N. , Zetterberg, H. , Tijms, B. M. , Teunissen, C. E. , Alvarez‐Cermeão, J. C. , Andreasson, U. , Axelsson, M. , Backstrãm, D. C. , Bartos, A. , Bjerke, M. , Blennow, K. , Boxer, A. , Brundin, L. , Burman, J. , Christensen, T. , Fialovã, L. , Forsgren, L. , Frederiksen, J. L. , … Gunnarsson, M. (2019). Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta‐analysis. JAMA Neurology, 76(9), 1035. 10.1001/jamaneurol.2019.1534 PubMed DOI PMC

Comabella, M. , Sastre‐Garriga, J. , Borras, E. , Villar, L. M. , Saiz, A. , Martínez‐Yélamos, S. , García‐Merino, J. A. , Pinteac, R. , Fissolo, N. , Sánchez López, A. J. , Costa‐Frossard, L. , Blanco, Y. , Llufriu, S. , Vidal‐Jordana, A. , Sabidó, E. , & Montalban, X. (2021). CSF chitinase 3‐Like 2 is associated with long‐term disability progression in patients with progressive multiple sclerosis. Neurology(R) Neuroimmunology & Neuroinflammation, 8(6), e1082. 10.1212/NXI.0000000000001082 PubMed DOI PMC

Filippi, M. , Bar‐Or, A. , Piehl, F. , Preziosa, P. , Solari, A. , Vukusic, S. , & Rocca, M. A. (2018). Multiple sclerosis. Nature Reviews Disease Primers, 4(1), 43. 10.1038/s41572-018-0041-4 PubMed DOI

Fischl, B. (2012). FreeSurfer. Neuroimage, 62(2), 774–781. 10.1016/j.neuroimage.2012.01.021 PubMed DOI PMC

Frischer, J. M. , Weigand, S. D. , Guo, Y. , Kale, N. , Parisi, J. E. , Pirko, I. , Mandrekar, J. , Bramow, S. , Metz, I. , Brãck, W. , Lassmann, H. , & Lucchinetti, C. F. (2015). Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Annals of Neurology, 78(5), 710–721. 10.1002/ana.24497 PubMed DOI PMC

Kalincik, T. , Vivek, V. , Jokubaitis, V. , Lechner‐Scott, J. , Trojano, M. , Izquierdo, G. , Lugaresi, A. , Grandâmaison, F. , Hupperts, R. , Oreja‐Guevara, C. , Bergamaschi, R. , Iuliano, G. , Alroughani, R. , Van Pesch, V. , Amato, M. P. , Slee, M. , Verheul, F. , Fernandez‐Bolanos, R. , Fiol, M. , & Spitaleri, D. L. (2013). Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 136(12), 3609–3617. 10.1093/brain/awt281 PubMed DOI

Kapoor, R. , Smith, K. E. , Allegretta, M. , Arnold, D. L. , Carroll, W. , Comabella, M. , Furlan, R. , Harp, C. , Kuhle, J. , Leppert, D. , Plavina, T. , Sellebjerg, F. , Sincock, C. , Teunissen, C. E. , Topalli, I. , Von Raison, F. , Walker, E. , & Fox, R. J. (2020). Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 95(10), 436–444. 10.1212/WNL.0000000000010346 PubMed DOI PMC

Khalil, M. , Enzinger, C. , Langkammer, C. , Ropele, S. , Mader, A. , Trentini, A. , Vane, M. , Wallner‐Blazek, M. , Bachmaier, G. , Archelos, J.‐J. , Koel‐Simmelink, M. , Blankenstein, M. , Fuchs, S. , Fazekas, F. , & Teunissen, C. (2013). CSF neurofilament and N‐acetylaspartate related brain changes in clinically isolated syndrome. Multiple Sclerosis Journal, 19(4), 436–442. 10.1177/1352458512458010 PubMed DOI PMC

Khalil, M. , Teunissen, C. E. , Otto, M. , Piehl, F. , Sormani, M. P. , Gattringer, T. , Barro, C. , Kappos, L. , Comabella, M. , Fazekas, F. , Petzold, A. , Blennow, K. , Zetterberg, H. , & Kuhle, J. (2018). Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 14(10), 577–589. 10.1038/s41582-018-0058-z PubMed DOI

Kosa, P. , Masvekar, R. , Komori, M. , Phillips, J. , Ramesh, V. , Varosanec, M. , Sandford, M. , & Bielekova, B. (2022). Enhancing the clinical value of serum neurofilament light chain measurement. JCI Insight, 7(15), e161415. 10.1172/jci.insight.161415 PubMed DOI PMC

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444–1444. 10.1212/wnl.33.11.1444 PubMed DOI

Ladang, A. L. , Kovacs, S. P. , Lengelã, L. , Locquet, M. D. A. , Reginster, J.‐Y. , Bruyãre, O. , & Cavalier, E. (2022). Neurofilament light chain concentration in an aging population. Aging Clinical and Experimental Research, 34(2), 331–339. 10.1007/s40520-021-02054-z PubMed DOI PMC

Manouchehrinia, A. , Piehl, F. , Hillert, J. , Kuhle, J. , Alfredsson, L. , Olsson, T. , & Kockum, I. (2020). Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Annals of Clinical and Translational Neurology, 7(1), 139–143. 10.1002/acn3.50972 PubMed DOI PMC

Martin, S.‐J. , Mcglasson, S. , Hunt, D. , & Overell, J. (2019). Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: A meta‐analysis of case‐control studies. Journal of Neurology, Neurosurgery and Psychiatry., 90(9), 1059–1067. 10.1136/jnnp-2018-319190 PubMed DOI PMC

Momtazmanesh, S. , Shobeiri, P. , Saghazadeh, A. , Teunissen, C. E. , Burman, J. , Szalardy, L. , Klivenyi, P. , Bartos, A. , Fernandes, A. , & Rezaei, N. (2021). Neuronal and glial CSF biomarkers in multiple sclerosis: A systematic review and meta‐analysis. Reviews in the Neurosciences, 32(6), 573–595. 10.1515/revneuro-2020-0145 PubMed DOI

Schmidt, P. , Gaser, C. , Arsic, M. , Buck, D. , Farschler, A. , Berthele, A. , Hoshi, M. , Ilg, R. , Schmid, V. J. , Zimmer, C. , Hemmer, B. , & Mahlau, M. (2012). An automated tool for detection of FLAIR‐hyperintense white‐matter lesions in multiple sclerosis. Neuroimage, 59(4), 3774–3783. 10.1016/j.neuroimage.2011.11.032 PubMed DOI

Schneider, R. , Bellenberg, B. , Gisevius, B. , Hirschberg, S. , Sankowski, R. , Prinz, M. , Gold, R. , Lukas, C. , & Haghikia, A. (2021). Chitinase 3‐like 1 and neurofilament light chain in CSF and CNS atrophy in MS. Neurology(R) Neuroimmunology & Neuroinflammation, 8(1), e906. 10.1212/NXI.0000000000000906 PubMed DOI PMC

Signori, A. , Schiavetti, I. , Gallo, F. , & Sormani, M. P. (2015). Subgroups of multiple sclerosis patients with larger treatment benefits: A meta‐analysis of randomized trials. European Journal of Neurology, 22(6), 960–966. 10.1111/ene.12690 PubMed DOI

Teunissen, C. , Menge, T. , Altintas, A. , Alvarez‐Cermeão, J. C. , Bertolotto, A. , Berven, F. S. , Brundin, L. , Comabella, M. , Degn, M. , Deisenhammer, F. , Fazekas, F. , Franciotta, D. , Frederiksen, J. L. , Galimberti, D. , Gnanapavan, S. , Hegen, H. , Hemmer, B. , Hintzen, R. , Hughes, S. , … Bartos, A. (2013). Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple Sclerosis Journal, 19(13), 1802–1809. 10.1177/1352458513488232 PubMed DOI

Thompson, A. J. , Banwell, B. L. , Barkhof, F. , Carroll, W. M. , Coetzee, T. , Comi, G. , Correale, J. , Fazekas, F. , Filippi, M. , Freedman, M. S. , Fujihara, K. , Galetta, S. L. , Hartung, H. P. , Kappos, L. , Lublin, F. D. , Marrie, R. A. , Miller, A. E. , Miller, D. H. , Montalban, X. , … Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. 10.1016/S1474-4422(17)30470-2 PubMed DOI

Tortorella, C. , Direnzo, V. , Ruggieri, M. , Zoccolella, S. , Mastrapasqua, M. , Dâonghia, M. , Paolicelli, D. , Dicuonzo, F. , Gasperini, C. , & Trojano, M. (2018). Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 24(8), 1039–1045. 10.1177/1352458517711774 PubMed DOI